655 related articles for article (PubMed ID: 30369518)
1. Interleukin-6 induces drug resistance in renal cell carcinoma.
Ishibashi K; Koguchi T; Matsuoka K; Onagi A; Tanji R; Takinami-Honda R; Hoshi S; Onoda M; Kurimura Y; Hata J; Sato Y; Kataoka M; Ogawsa S; Haga N; Kojima Y
Fukushima J Med Sci; 2018 Dec; 64(3):103-110. PubMed ID: 30369518
[TBL] [Abstract][Full Text] [Related]
2. Humanised antihuman IL-6R antibody with interferon inhibits renal cell carcinoma cell growth in vitro and in vivo through suppressed SOCS3 expression.
Oguro T; Ishibashi K; Sugino T; Hashimoto K; Tomita S; Takahashi N; Yanagida T; Haga N; Aikawa K; Suzutani T; Yamaguchi O; Kojima Y
Eur J Cancer; 2013 May; 49(7):1715-24. PubMed ID: 23274199
[TBL] [Abstract][Full Text] [Related]
3. Overriding TKI resistance of renal cell carcinoma by combination therapy with IL-6 receptor blockade.
Ishibashi K; Haber T; Breuksch I; Gebhard S; Sugino T; Kubo H; Hata J; Koguchi T; Yabe M; Kataoka M; Ogawa S; Hiraki H; Yanagida T; Haga N; Thüroff JW; Prawitt D; Brenner W; Kojima Y
Oncotarget; 2017 Aug; 8(33):55230-55245. PubMed ID: 28903416
[TBL] [Abstract][Full Text] [Related]
4. Suppression of SOCS3 increases susceptibility of renal cell carcinoma to interferon-α.
Tomita S; Ishibashi K; Hashimoto K; Sugino T; Yanagida T; Kushida N; Shishido K; Aikawa K; Sato Y; Suzutani T; Yamaguchi O
Cancer Sci; 2011 Jan; 102(1):57-63. PubMed ID: 21054677
[TBL] [Abstract][Full Text] [Related]
5. Overcoming sunitinib resistance with tocilizumab in renal cell carcinoma: Discordance between in vitro and in vivo effects.
Kamli H; Owens EP; Vesey DA; Prasanna R; Li L; Gobe GC; Morais C
Biochem Biophys Res Commun; 2022 Jan; 586():42-48. PubMed ID: 34826699
[TBL] [Abstract][Full Text] [Related]
6. Advanced renal cell carcinoma: current and emerging management strategies.
Escudier B
Drugs; 2007; 67(9):1257-64. PubMed ID: 17547470
[TBL] [Abstract][Full Text] [Related]
7. Growth inhibitory effect of an injectable hyaluronic acid-tyramine hydrogels incorporating human natural interferon-α and sorafenib on renal cell carcinoma cells.
Ueda K; Akiba J; Ogasawara S; Todoroki K; Nakayama M; Sumi A; Kusano H; Sanada S; Suekane S; Xu K; Bae KH; Kurisawa M; Igawa T; Yano H
Acta Biomater; 2016 Jan; 29():103-111. PubMed ID: 26481041
[TBL] [Abstract][Full Text] [Related]
8. 6-Hydroxy-3-O-methyl-kaempferol 6-O-glucopyranoside potentiates the anti-proliferative effect of interferon α/β by promoting activation of the JAK/STAT signaling by inhibiting SOCS3 in hepatocellular carcinoma cells.
Wonganan O; He YJ; Shen XF; Wongkrajang K; Suksamrarn A; Zhang GL; Wang F
Toxicol Appl Pharmacol; 2017 Dec; 336():31-39. PubMed ID: 29031523
[TBL] [Abstract][Full Text] [Related]
9. Upregulated production of IL-6, but not IL-10, by interferon-alpha induces SOCS3 expression and attenuates STAT1 phosphorylation in myeloma cells.
Usui E; Nishii K; Katayama N; Lorenzo V F; Chen F; Monma F; Otsuki T; Shiku H
Hematol J; 2004; 5(6):505-12. PubMed ID: 15570293
[TBL] [Abstract][Full Text] [Related]
10. Suppression of SOCS3 enhances TRAIL-induced cell growth inhibition through the upregulation of DR4 expression in renal cell carcinoma cells.
Yabe M; Ishibashi K; Onagi A; Tanji R; Honda-Takinami R; Koguchi T; Matsuoka K; Hoshi S; Hata J; Kataoka M; Ogawa S; Hiraki H; Haga N; Kojima Y
Oncotarget; 2018 Aug; 9(60):31697-31708. PubMed ID: 30167088
[TBL] [Abstract][Full Text] [Related]
11. Acquired resistance to sunitinib in human renal cell carcinoma cells is mediated by constitutive activation of signal transduction pathways associated with tumour cell proliferation.
Sakai I; Miyake H; Fujisawa M
BJU Int; 2013 Jul; 112(2):E211-20. PubMed ID: 23305097
[TBL] [Abstract][Full Text] [Related]
12. Human renal carcinoma line transfected with interleukin-2 and/or interferon alpha gene(s): implications for live cancer vaccines.
Belldegrun A; Tso CL; Sakata T; Duckett T; Brunda MJ; Barsky SH; Chai J; Kaboo R; Lavey RS; McBride WH
J Natl Cancer Inst; 1993 Feb; 85(3):207-16. PubMed ID: 8423625
[TBL] [Abstract][Full Text] [Related]
13. Potential new therapy of Rapalink-1, a new generation mammalian target of rapamycin inhibitor, against sunitinib-resistant renal cell carcinoma.
Kuroshima K; Yoshino H; Okamura S; Tsuruda M; Osako Y; Sakaguchi T; Sugita S; Tatarano S; Nakagawa M; Enokida H
Cancer Sci; 2020 May; 111(5):1607-1618. PubMed ID: 32232883
[TBL] [Abstract][Full Text] [Related]
14. Antitumor effects of a combination of interferon-alpha and sorafenib on human renal carcinoma cell lines.
Tochizawa S; Masumori N; Yanai Y; Ohmoto Y; Yabuuchi Y; Tsukamoto T
Biomed Res; 2008 Dec; 29(6):271-8. PubMed ID: 19129670
[TBL] [Abstract][Full Text] [Related]
15. Recent advances and future directions in the management of metastatic renal cell carcinoma.
Ansari J; Glaholm J; McMenemin R; James ND; Hussain SA
Anticancer Agents Med Chem; 2010 Mar; 10(3):225-35. PubMed ID: 20184547
[TBL] [Abstract][Full Text] [Related]
16. Defective Jak-Stat activation in renal cell carcinoma is associated with interferon-alpha resistance.
Shang D; Liu Y; Ito N; Kamoto T; Ogawa O
Cancer Sci; 2007 Aug; 98(8):1259-64. PubMed ID: 17573897
[TBL] [Abstract][Full Text] [Related]
17. Thyroid dysfunction and tyrosine kinase inhibitors in renal cell carcinoma.
Bianchi L; Rossi L; Tomao F; Papa A; Zoratto F; Tomao S
Endocr Relat Cancer; 2013 Oct; 20(5):R233-45. PubMed ID: 23833016
[TBL] [Abstract][Full Text] [Related]
18. In vitro modulation of the invasive and metastatic potentials of human renal cell carcinoma by interleukin-2 and/or interferon-alpha gene transfer.
Hathorn RW; Tso CL; Kaboo R; Pang S; Figlin R; Sawyers C; deKernion JB; Belldegrun A
Cancer; 1994 Oct; 74(7):1904-11. PubMed ID: 7521786
[TBL] [Abstract][Full Text] [Related]
19. Growth and major histocompatibility antigen expression regulation by IL-4, interferon-gamma (IFN-gamma) and tumour necrosis factor-alpha (TNF-alpha) on human renal cell carcinoma.
Hillman GG; Puri RK; Kukuruga MA; Pontes JE; Haas GP
Clin Exp Immunol; 1994 Jun; 96(3):476-83. PubMed ID: 8004818
[TBL] [Abstract][Full Text] [Related]
20. SOX9 was involved in TKIs resistance in renal cell carcinoma via Raf/MEK/ERK signaling pathway.
Li XL; Chen XQ; Zhang MN; Chen N; Nie L; Xu M; Gong J; Shen PF; Su ZZ; Weng X; Tan JY; Zhao T; Zeng H; Zhou Q
Int J Clin Exp Pathol; 2015; 8(4):3871-81. PubMed ID: 26097571
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
